Nuclera’s cover photo
Nuclera

Nuclera

Biotechnology Research

Cambridge, Cambridgeshire 16,191 followers

Bring rapid protein access to your benchtop with eProtein Discovery

About us

At Nuclera, our mission is to better human health by making proteins accessible. We believe that providing rapid access to high-quality, soluble, active proteins at the benchtop will allow researchers to accelerate their protein projects. Fail fast, succeed faster. Our eProtein Discovery™ system automates construct screening for the best soluble expression and purification yields of different proteins in under 24 hours. From there, protein scale-up happens the next day (up to the mg scale) right on the benchtop - delivering reliable protein in-hand in less than 48 hours. Nuclera’s technology integrates cell-free protein synthesis and digital microfluidics on smart cartridges, allowing rapid progress on protein projects through a benchtop, automated, high-throughput protein access system. Founded in 2013 by PhD students at the University of Cambridge, the company now has a presence in Cambridge, UK and Boston, MA employing over 100 employees.

Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
Cambridge, Cambridgeshire
Type
Privately Held
Founded
2013
Specialties
protein production, protein synthesis, and protein optimisation

Locations

  • Primary

    One Vision Park

    Chivers Way, Histon

    Cambridge, Cambridgeshire CB24 9LF, GB

    Get directions
  • 1000 Technology Park Dr

    Suite B

    Billerica, MA 01821, US

    Get directions

Employees at Nuclera

Updates

  • Nuclera reposted this

    View profile for Michael Chen

    Making proteins accessible as CEO of Nuclera

    Do we use #AI at Nuclera? Yes. But not always in the way you might think. 𝗪𝗲 𝘂𝘀𝗲 𝗔𝗜 𝘁𝗼 𝗺𝗮𝗸𝗲 𝗽𝗿𝗼𝘁𝗲𝗶𝗻 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗿𝗲𝗹𝗶𝗮𝗯𝗹𝗲. Our 𝗲𝗣𝗿𝗼𝘁𝗲𝗶𝗻 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 software tracks every droplet moved by our digital microfluidic technology, ensuring each step of the screening workflow is executed precisely. This gives protein scientists confidence that their screening data is both accurate and reproducible. 𝗪𝗵𝘆 𝗱𝗼𝗲𝘀 𝘁𝗵𝗶𝘀 𝗺𝗮𝘁𝘁𝗲𝗿? With digital microfluidics, we "instruct" droplets to move, split, merge, or stretch -- but how do we confirm the droplets actually behave as expected? That’s where our 𝗲𝗣𝗿𝗼𝘁𝗲𝗶𝗻 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 software comes in. Our software uses AI to evaluate droplet motion, flag deviations, and, in the future, will dynamically correct droplet errors -- ensuring every data point is trustworthy. 𝗔𝗜 𝗶𝗻 𝗣𝗿𝗼𝘁𝗲𝗶𝗻 𝗗𝗲𝘀𝗶𝗴𝗻? We worked with Google (Google Cloud) to integrate #AlphaFold2 into our 𝗲𝗣𝗿𝗼𝘁𝗲𝗶𝗻 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 cloud software and plan to push this feature as an update later this year to bring easily accessible structure prediction directly into protein design workflows. Stay tuned for more information. Beyond that, we’re actively working with companies applying AI to protein design and structure prediction -- helping them turn cutting-edge algorithms into real proteins. If you're facing challenges validating an AI-designed protein -- or just trying to express a sequence straight from UniProt -- let’s talk. #ProteinScience #DigitalMicrofluidics #LabAutomation #AIinBiotech

    • No alternative text description for this image
  • 𝗦𝘁𝗿𝘂𝗴𝗴𝗹𝗶𝗻𝗴 𝘁𝗼 𝗴𝗲𝘁 𝘀𝗼𝗹𝘂𝗯𝗹𝗲, 𝗮𝗰𝘁𝗶𝘃𝗲 𝗺𝗲𝗺𝗯𝗿𝗮𝗻𝗲 𝗽𝗿𝗼𝘁𝗲𝗶𝗻𝘀? The eProtein Discovery™ System now enables rapid 𝗺𝗲𝗺𝗯𝗿𝗮𝗻𝗲 𝗽𝗿𝗼𝘁𝗲𝗶𝗻 𝗲𝘅𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻 𝗮𝗻𝗱 𝘀𝘁𝗮𝗯𝗶𝗹𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴, delivering high-quality membrane proteins 𝗶𝗻 𝘂𝗻𝗱𝗲𝗿 𝟰𝟴 𝗵𝗼𝘂𝗿𝘀 — 𝗿𝗲𝗮𝗱𝘆 𝗳𝗼𝗿 𝗖𝗿𝘆𝗼-𝗘𝗠 𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲 𝗱𝗲𝘁𝗲𝗿𝗺𝗶𝗻𝗮𝘁𝗶𝗼𝗻 𝗼𝗿 𝗳𝘂𝗻𝗰𝘁𝗶𝗼𝗻𝗮𝗹 𝘀𝘁𝘂𝗱𝗶𝗲𝘀. Our integrated nanodisc and detergent screening technology streamlines stabilization condition identification, accelerating breakthroughs in structural biology and drug discovery. Now supporting both soluble and membrane proteins, it offers a comprehensive solution for diverse protein expression and purification needs. Join our live webinar and learn how eProtein Discovery can revolutionize your process. Rapidly Express Optimized Membrane Proteins in 48 hours 📅 Date: Thursday, March 27 🕚 Time: 11AM US / 3PM UK You’ll learn about: 🔬 How eProtein Discovery™ improves expression success in challenging proteins, including membrane proteins 📖 Case studies on DHODH and MsbA, demonstrating protein production optimized for cryo-EM and functional assays 🧪 How eProtein Discovery generates proteins that are ready to use for downstream applications, including structural biology and activity studies 👉Sign up now: https://eprote.in/MP48 #proteinaccess #proteins #biotech

    • Webinar

March 27, 2025
11 AM (EDT) |  3 PM (UK)

Rapidly Express Optimized Membrane Proteins in 48 hours

Speaker: Toby Ost
(SVP Product Development)
  • What does AI on eProtein Discovery look like? Check it out!

    View profile for Michael Chen

    Making proteins accessible as CEO of Nuclera

    Do we use #AI at Nuclera? Yes. But not always in the way you might think. 𝗪𝗲 𝘂𝘀𝗲 𝗔𝗜 𝘁𝗼 𝗺𝗮𝗸𝗲 𝗽𝗿𝗼𝘁𝗲𝗶𝗻 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗿𝗲𝗹𝗶𝗮𝗯𝗹𝗲. Our 𝗲𝗣𝗿𝗼𝘁𝗲𝗶𝗻 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 software tracks every droplet moved by our digital microfluidic technology, ensuring each step of the screening workflow is executed precisely. This gives protein scientists confidence that their screening data is both accurate and reproducible. 𝗪𝗵𝘆 𝗱𝗼𝗲𝘀 𝘁𝗵𝗶𝘀 𝗺𝗮𝘁𝘁𝗲𝗿? With digital microfluidics, we "instruct" droplets to move, split, merge, or stretch -- but how do we confirm the droplets actually behave as expected? That’s where our 𝗲𝗣𝗿𝗼𝘁𝗲𝗶𝗻 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 software comes in. Our software uses AI to evaluate droplet motion, flag deviations, and, in the future, will dynamically correct droplet errors -- ensuring every data point is trustworthy. 𝗔𝗜 𝗶𝗻 𝗣𝗿𝗼𝘁𝗲𝗶𝗻 𝗗𝗲𝘀𝗶𝗴𝗻? We worked with Google (Google Cloud) to integrate #AlphaFold2 into our 𝗲𝗣𝗿𝗼𝘁𝗲𝗶𝗻 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 cloud software and plan to push this feature as an update later this year to bring easily accessible structure prediction directly into protein design workflows. Stay tuned for more information. Beyond that, we’re actively working with companies applying AI to protein design and structure prediction -- helping them turn cutting-edge algorithms into real proteins. If you're facing challenges validating an AI-designed protein -- or just trying to express a sequence straight from UniProt -- let’s talk. #ProteinScience #DigitalMicrofluidics #LabAutomation #AIinBiotech

    • No alternative text description for this image
  • 🚀 Nuclera welcomes Seth Benson as Chief Financial Officer! 🚀 We’re excited to announce the appointment of Seth Benson as our new CFO, joining CEO Dr. Michael Chen to drive Nuclera’s next phase of commercial growth and global expansion. Seth brings 20+ years of experience in finance, strategy, and operations within life sciences, having played key roles in scaling companies like Akoya Biosciences, Inc. and Vizgen. His expertise will be instrumental as we accelerate the rollout of our eProtein Discovery™ system, empowering scientists to overcome critical protein production bottlenecks. 💡 Seth Benson, CFO, Nuclera: "Nuclera’s eProtein Discovery system has the potential to transform protein workflows and impact drug discovery. I’m thrilled to join at such an exciting time and look forward to driving growth with this incredible team." Join us in welcoming Seth to Nuclera! 🎉 🔗 Connect with Seth Benson 🔗 See our full Press Release: https://eprote.in/seth-cfo

    • No alternative text description for this image
  • Nuclera reposted this

    View profile for Michael Chen

    Making proteins accessible as CEO of Nuclera

    𝗠𝗶𝗰𝗿𝗼𝗳𝗹𝘂𝗶𝗱𝗶𝗰 𝗺𝗮𝗴𝗶𝗰 𝗶𝗻 𝗮𝗰𝘁𝗶𝗼𝗻.  What you’re seeing: thousands of nanoliter droplets moving with digital precision—no channels, just signals. That’s digital microfluidics brought to you by Nuclera. 𝗪𝗵𝗮𝘁 𝗱𝗼𝗲𝘀 𝗶𝘁 𝗺𝗲𝗮𝗻 𝗳𝗼𝗿 𝘆𝗼𝘂? We take the pain out of protein production screening. By combining: • Digital microfluidics (moves liquids) • Cell-free protein synthesis (make proteins from DNA) • Magnetic protein purification (purifies proteins made) • Fluorescent protein characterization assay (yield & quality of proteins made) …we turn weeks or months of screening work 𝗶𝗻𝘁𝗼 𝟮𝟰 𝗵𝗼𝘂𝗿𝘀. 𝗧𝗵𝗲 𝗿𝗲𝘀𝘂𝗹𝘁𝘀? “𝗜 𝗺𝗮𝗱𝗲 𝗽𝗿𝗼𝘁𝗲𝗶𝗻 𝗜 𝗻𝗲𝘃𝗲𝗿 𝗴𝗼𝘁 𝗯𝗲𝗳𝗼𝗿𝗲.” That’s what we hear from our customers. With a 93% soluble protein obtainability rate (yes, 93% including many difficult human proteins) and membrane proteins on the way, we’re redefining what's possible. 𝗦𝗼𝗺𝗲 𝗺𝗼𝗿𝗲 𝗱𝗲𝘁𝗮𝗶𝗹𝘀 𝗳𝗼𝗿 𝘁𝗵𝗼𝘀𝗲 𝗼𝗳 𝘆𝗼𝘂 𝗶𝗻𝘁𝗲𝗿𝗲𝘀𝘁𝗲𝗱... Digital microfluidics works through a physical phenomena called electrowetting on dielectric (EWOD). We partnered with E Ink Corporation and Prof Hywel Morgan to get it to work. #DigitalMicrofluidics #eProteinDiscovery

    • No alternative text description for this image
  • 🚀 Welcoming William J. Kullback to Nuclera’s Board! 🚀 We’re thrilled to announce that William Kullback has joined Nuclera as a Non-Executive Director (NED)! 🎉 With over 30 years of financial leadership experience in life sciences and a track record of driving growth—most notably leading BioLegend’s $5.25B acquisition—William brings invaluable expertise as we continue to expand globally.  🔹 Current CFO at Telesis Bio  🔹 Former CFO at BioLegendLombard Endovastec  🔹 Expert in M&A and public market success 💡  “𝘕𝘶𝘤𝘭𝘦𝘳𝘢’𝘴 𝘦𝘗𝘳𝘰𝘵𝘦𝘪𝘯 𝘋𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺™ 𝘩𝘢𝘴 𝘵𝘩𝘦 𝘱𝘰𝘵𝘦𝘯𝘵𝘪𝘢𝘭 𝘵𝘰 𝘵𝘳𝘢𝘯𝘴𝘧𝘰𝘳𝘮 𝘥𝘳𝘶𝘨 𝘥𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺 𝘸𝘰𝘳𝘬𝘧𝘭𝘰𝘸𝘴. 𝘐’𝘮 𝘦𝘹𝘤𝘪𝘵𝘦𝘥 𝘵𝘰 𝘴𝘶𝘱𝘱𝘰𝘳𝘵 𝘵𝘩𝘦 𝘵𝘦𝘢𝘮 𝘢𝘵 𝘵𝘩𝘪𝘴 𝘱𝘪𝘷𝘰𝘵𝘢𝘭 𝘴𝘵𝘢𝘨𝘦 𝘰𝘧 𝘨𝘳𝘰𝘸𝘵𝘩.” – William Kullback We look forward to the impact William will have as we scale eProtein Discovery™ to help researchers tackle today’s biggest protein production challenges. Join us in welcoming William to the team! 👏   Read the full announcement here: https://lnkd.in/enJc2T7r #Leadership #Biotech #Nuclera #ProteinScience

    • No alternative text description for this image

Similar pages

Browse jobs

Funding